Glaxo Fund Looks for Early-Stage Alzheimer’s Detectors

GlaxoSmithKline Plc’s venture-capital fund is seeking to invest in a biotechnology company that has both a brain-imaging dye to detect warning signs for Alzheimer’s disease and a drug treatment for the ailment.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.